Iovance Biotherapeutics, Inc. Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics, Inc.

IOVA

Rangering i aksjer #2795
Iovance Biotherapeutics, Inc., a biotechnology firm currently in the clinical... Iovance Biotherapeutics, Inc., a biotechnology firm currently in the clinical development stage, is committed to discovering and bringing to market cancer immunotherapy solutions. Its core mission involves leveraging the patient's own immune system to effectively combat and eradicate cancerous cells. The company is presently conducting six Phase 2 clinical trials. These include study C-144-01, evaluating its primary experimental compound, lifileucel, for individuals with advanced melanoma. Another trial, C-145-04, is assessing lifileucel's potential for treating cervical cancer that is recurrent, metastatic, or persistent. Additionally, investigational product LN-145 is undergoing evaluation in trial C-145-03 for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. maintains strategic alliances and licensing arrangements with several distinguished entities, including H. Lee Moffitt Cancer Center, M.D. Anderson Cancer Center, Ohio State University, the Centre hospitalier de l'Université de Montreal, Cellectis S.A., and Novartis Pharma AG. Established in 2007, the company was previously known as Lion Biotechnologies, Inc. It adopted its current name, Iovance Biotherapeutics, Inc., in June 2017. Its corporate offices are located in San Carlos, California.
Aksjekurs
$14.87
Sist synkronisert: 2026-10-20
Markedsverdi
$6.74B
Endring (1 dag)
4.64%
Endring (1 år)
555.03%
Land
US
Handel Iovance Biotherapeutics, Inc. (IOVA)

Kategori

Healthcare
Historikk for aksjesplitt for Iovance Biotherapeutics, Inc. (IOVA)
Aksjen Iovance Biotherapeutics, Inc. (symbol: IOVA) har gjennomgått totalt 2 aksjesplitt.
Den nyeste splittelsen skjedde Sep 26, 2013.
Én IOVA-aksje kjøpt før May 26, 2010 tilsvarer i dag 0.23999 IOVA-aksjer.
Liste over aksjesplitt
År Splitt Multiplikator Kumulativ multiplikator
2013-09-26 1:100 x0.01 x0.23999
2010-05-26 23999:1000 x23.999 x23.999
Aksjesplitt for lignende selskaper eller konkurrenter
Selskap Antall aksjesplitt Kumulativ multiplikator Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 1 x2
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 0 -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 1 x3
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 0 -
CH
Argenx SE Argenx SE
Argenx SE
ARGX.US
 0 -
NL